SANTEN, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 1993-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.santeninc.com
A Phase I/II Safety, Tolerability, Immunogenicity, and Bioactivity Study of DE-122 Injectable Solution for Refractory Exudative Age-related Macular Degeneration
Phase 1
Completed
- Conditions
- Age-Related Macular Degeneration
- Interventions
- Drug: 0.5 mg of DE-122Drug: 2.0 mg of DE-122Drug: 1.0 mg of DE-122Drug: 4.0 mg of DE-122
- First Posted Date
- 2015-09-21
- Last Posted Date
- 2020-01-14
- Lead Sponsor
- Santen Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT02555306
A Safety and Efficacy Study of DE-120 Injectable Solution for Age-related Macular Degeneration
Phase 2
Completed
- Conditions
- Age-Related Macular Degeneration
- Interventions
- First Posted Date
- 2015-03-30
- Last Posted Date
- 2018-04-18
- Lead Sponsor
- Santen Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT02401945
A Phase IIIb, Multinational, Multicenter, Open-Label Extension Study Assessing the Long-Term Safety of PRN Intravitreal Injections of DE-109 in Subjects With Non-Infectious Uveitis of the Posterior Segment of the Eye Who Have Participated in the SAKURA Development Program
Phase 3
Completed
- Conditions
- Non-Infectious Uveitis of the Posterior Segment of the Eye
- Interventions
- Drug: DE-109 440 μg
- First Posted Date
- 2014-09-29
- Last Posted Date
- 2020-02-12
- Lead Sponsor
- Santen Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT02251938
Multi-center Phase II Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension
Phase 2
Completed
- Conditions
- Open-angle GlaucomaOcular Hypertension
- Interventions
- Drug: DE-117 Low Dose ophthalmic solutionDrug: DE-117 Low/Middle Dose ophthalmic solutionDrug: DE-117 Middle Dose ophthalmic solutionDrug: DE-117 Middle/High Dose ophthalmic solutionDrug: DE-117 High Dose ophthalmic solution
- First Posted Date
- 2014-07-01
- Last Posted Date
- 2018-04-18
- Lead Sponsor
- Santen Inc.
- Target Recruit Count
- 184
- Registration Number
- NCT02179008
A Phase I/II Safety Study of DE-120 Injectable Solution for Age-related Macular Degeneration
- First Posted Date
- 2013-12-27
- Last Posted Date
- 2018-04-18
- Lead Sponsor
- Santen Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT02022501
Multi-center Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension
Phase 2
Completed
- Conditions
- Open-angle Glaucoma or Ocular Hypertension
- Interventions
- First Posted Date
- 2013-06-04
- Last Posted Date
- 2018-04-18
- Lead Sponsor
- Santen Inc.
- Target Recruit Count
- 91
- Registration Number
- NCT01868126
A Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Patients With POAG or OHT
Phase 1
Completed
- Conditions
- Glaucoma and Ocular Hypertension
- Interventions
- First Posted Date
- 2012-07-31
- Last Posted Date
- 2018-04-18
- Lead Sponsor
- Santen Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT01654484
- Locations
- 🇺🇸
Santen Investigational Site, San Antonio, Texas, United States
A Study Assessing the Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients
Phase 2
Completed
- Conditions
- Dry Eye Disease
- Interventions
- Drug: DE-101 Ophthalmic SuspensionDrug: DE-101 Ophthalmic Suspension Vehicle
- First Posted Date
- 2011-11-09
- Last Posted Date
- 2012-12-17
- Lead Sponsor
- Santen Inc.
- Target Recruit Count
- 183
- Registration Number
- NCT01468168
Study Assessing Double-masked Uveitis Treatment
Phase 3
Completed
- Conditions
- Uveitis; Posterior, Disorder
- Interventions
- Drug: DE-109 880 ugDrug: DE-109 44 ugDrug: DE-109 440 ug
- First Posted Date
- 2011-05-23
- Last Posted Date
- 2019-07-16
- Lead Sponsor
- Santen Inc.
- Target Recruit Count
- 592
- Registration Number
- NCT01358266
Safety and Efficacy Trial to Treat Open-Angle Glaucoma or Ocular Hypertension
Phase 1
Completed
- Conditions
- Open-angle GlaucomaOcular Hypertension
- Interventions
- First Posted Date
- 2011-01-19
- Last Posted Date
- 2012-12-17
- Lead Sponsor
- Santen Inc.
- Target Recruit Count
- 147
- Registration Number
- NCT01279083
© Copyright 2025. All Rights Reserved by MedPath